Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 2250 Equity Shares pursuant to exercise of ESOP options.

Corporate Office: Solara Active Pharma Sciences Limited TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in Website: www.solara.co.in Date: July 23, 2026 The BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G, Bandra-Kurla Dalal Street, Mumbai – 400 001 Complex, Bandra (E), Mumbai – 400 051 Scrip Code: 541540, 890202 Symbol: SOLARA, SOLARAPP1 Dear Sir/Madam, Sub: Allotment of 2,250 Equity Shares pursuant to exercise of Options under Solara Employee Stock Option Plan 2018 - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) This is to inform you that the Board of Directors of Solara Active Pharma Sciences Limited (“Company”) by way of Board Resolution passed at the Board Meeting today i.e. Thursday, July 23, 2026, has approved: Allotment of 2,250 Equity Shares pursuant to Exercise of Options under Solara Employee Stock Option Plan 2018. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and Regulation 10(c) of Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, (“SEBI SBEB & SE Regulations”), the Board of Directors have approved the allotment of 2,250 (Two Thousand Two Hundred and Fifty) Equity Shares of face value Rs. 10/- each fully paid up against the exercise of vested Options of Solara Employee Stock Option Plan 2018. The equity shares so allotted under the aforesaid Scheme, shall rank pari-passu with the existing equity shares of the Company in all respects. Consequent to the aforesaid allotment, the paid‐up share capital of the Company will accordingly increase as follows: Paid up capital before ESOP allotment Sl. No Type No of shares Paid up (In Rs.) Amount (In Rs.) 1 Equity Shares - Fully Paid 4,77,97,735 10 47,79,77,350.00 2 Equity Shares - Partly Paid 2,82,470 7 19,77,290.00 3 Equity Shares - Partly Paid 1,65,807 3.5 5,80,324.50 Total Paid up capital 4,82,46,012 48,05,34,964.50 Paid up capital post ESOP allotment Sl. No Type No of shares Paid up (In Rs.) Amount (In Rs.) 1 Equity Shares - Fully Paid 4,77,99,985 10 47,79,99,850.00 2 Equity Shares - Partly Paid 2,82,470 7 19,77,290.00 3 Equity Shares - Partly Paid 1,65,807 3.5 5,80,324.50 Total Paid up capital 4,82,48,262 48,05,57,464.50 Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636 Registered Office: 9th Floor, ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703; Tel: +91-22-20870033 Corporate Office: Solara Active Pharma Sciences Limited TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in Website: www.solara.co.in In terms of Regulation 10(c) read with Part – E of the SEBI SBEB & SE Regulations, the details of the shares allotted are enclosed herewith as “Annexure-A” and the details required as per Master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as “Annexure -B”. We request you to take the same on record. Thanking you, Yours faithfully, For Solara Active Pharma Sciences Limited Pooja Jaya Kumar Company Secretary & Compliance Officer Membership No: A57415 Encl.: As above Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636 Registered Office: 9th Floor, ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703; Tel: +91-22-20870033 Corporate Office: Solara Active Pharma Sciences Limited TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in Website: www.solara.co.in Annexure-A Disclosure under Part E pursuant to Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 1 Company name and address of Registered Solara Active Pharma Sciences Limited Office ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703 2 Name of the Stock Exchange on which the 1. National Stock Exchange of India Limited company’s shares are listed 2. BSE Limited 3 Filing date of the statement referred in • NSE: November 16, 2018 Regulation 10(b) of the Securities and • BSE: November 16, 2018 Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognized Stock Exchange 4 Filing Number, if any • NSE: NSE/LIST/19224 • BSE: DCS/IPO/JR/ESOP-IP/3352/2018-19 5 Title of the Scheme pursuant to which Solara Employee Stock Option Plan, 2018 shares are issued, if any 6 Kind of security to be listed Equity shares 7 Par value of the shares Rs.10/‐ per Equity Share 8 Date of issue of shares June 28, 2024 9 Number of shares issued 2,250 Equity shares 10 Share Certificate No., if applicable Not Applicable 11 Distinctive number of the share, if From: 48246013 To: 48248262 applicable: 12 ISIN Number of the shares if issued in INE624Z01016 Demat 13 Exercise price per share Rs. 375/- 14 Premium per share Rs. 365/- 15 Total shares issued after this issue 4,82,48,262 Equity Shares at Rs. 10/- each 16 Total issued share capital after this issue Rs. 48,24,82,620 /- 17 Details of any lock-in on the shares Not Applicable 18 Date of expiry of lock-in Not Applicable Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636 Registered Office: 9th Floor, ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703; Tel: +91-22-20870033 Corporate Office: Solara Active Pharma Sciences Limited TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in Website: www.solara.co.in Whether shares are identical in all respects Shares issued shall rank pari- passu with the 19 to existing shares? If not, when will they existing equity shares of the company become identical? 20 Details of listing fees, if payable Not Applicable Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636 Registered Office: 9th Floor, ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703; Tel: +91-22-20870033 Corporate Office: Solara Active Pharma Sciences Limited TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in Website: www.solara.co.in Annexure – B Disclosure under Regulation 30 of SEBI (LODR) Regulation 2015 read Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Sr. No. Particulars Details Solara Employee Stock Option Plan 2018 – June 28, 2024 1 Brief details of options granted Options Granted - 7,500 Options Vested - 2,250 Options Exercised - 2,250 Whether the scheme is in terms of the Securities and Exchange Board of India (Share Based 2 Employee Benefits and Sweat Equity) Yes Regulations, 2021 ('SBEB & SE Regulations'), if applicable 2,250 Equity Shares of face value of Rs. 10/- each to be issued against 2,250 3 Total number of shares covered by these options Options under Solara Employee Stock Option Plan 2018 upon exercise. 4 Pricing Formula/ Exercise Price Exercise Price is Rs. 375/- per share 5 Options Vested 2,250 options vested. Options shall be exercised within 120 days from the date of Vesting of the Options within which an Employee should exercise his/ her right to apply 6 Time within which options may be exercised for Shares against the vested Option in pursuance of the Plan. The Options shall not be permitted to be exercised after the [Showing first 8,000 characters — download PDF for full document]